

**FOR IMMEDIATE RELEASE**

**For further information contact:**

Stephanie Perri, CSA Medical  
+1-781-538-4794 / sperry@csamedical.com

**CSA Medical Announces the Presentation of the truFreeze® System Pulmonary Studies at WCBIP and ATS**

Results from the truFreeze® spray cryotherapy registry and independent clinical studies will be presented at WCBIP and ATS in May 2016

**Boston, MA – May 3, 2016:** Researchers from leading academic healthcare institutions and CSA Medical, Inc. announce the acceptance of abstracts at the World Congress of Bronchology and Interventional Pulmonology (WCBIP) and American Thoracic Society (ATS) meetings. These abstracts will provide details about studies conducted using truFreeze® liquid nitrogen spray cryotherapy in the central airway. The WCBIP Congress will take place May 8-11 in Florence, Italy. The ATS conference will take place May 13-18 in San Francisco, CA.

truFreeze® Oral Presentations at the WCBIP Conference

**Tuesday, May 10**

8:30AM-10:30AM, Sala Ottagonale

*Spray Cryotherapy in Benign Tracheobronchial Disease: An Illustration of Procedural Techniques*

Presenter: Scott Parish

Session: Bronchoscopy in benign disorders of central airways

**Wednesday, May 11**

9:00AM-10:30AM, Sala Ottagonale

*Spray Cryotherapy (SCT) in Pulmonary Disease: Interim analysis of a multi- center registry*

Presenter: Robert Browning

Session: Lung Cancer

truFreeze® Poster Presentation at the ATS Conference

**Monday, May 16**

9:00AM-4:15PM

*Safety of Airway TruFreeze® Spray Cryotherapy for Benign Proximal Tracheal Stenosis with Flexible Bronchoscopy and Laryngeal Mask Airway (ID 9240)*

Investigators: Diana H. Yu, Scott S. Oh, Irawan Susanto

Thematic Poster Session: B39-INTERVENTIONAL PULMONARY MEDICINE: RECENT ADVANCES

“The interim registry results presented at WCBIP support other peer-reviewed publications related to the safety and efficacy of the use of liquid nitrogen in the central airway to ablate both benign and malignant tissues. We look forward to continuing support of this registry and the participating physicians and patients as well as the reporting of longer-term follow up within this patient population,” remarked Ellen Sheets, M.D., CEO and President of CSA Medical. “In addition, the use of a LMA with spray cryotherapy has not yet been published and is an important peer education piece allowing the authors to share their clinical experience in this area of anesthesia management at ATS.”

#### **About the Registry (NCT01802203)**

Patients were enrolled prospectively from institutions using truFreeze® SCT to ablate benign or malignant unwanted tissue in the central airways or pleura. The primary objective of this registry is to collect efficacy, safety and specific patient data related to the use of truFreeze® spray cryotherapy in the pulmonary setting. Participating centers include:

- Walter Reed National Military Medical Center, Bethesda, MD
- New York University Langone School of Medicine, New York, NY
- University of Maryland School of Medicine, Baltimore, MD

More information about the patient registry can be found here:

<https://clinicaltrials.gov/ct2/show/NCT01802203>

#### **About CSA Medical**

CSA Medical is committed to advancing the science of non-contact spray cryotherapy. We provide rejuvenative ablation solutions using liquid nitrogen, enabling physicians to improve their patients’ continuum of care since 2006. To learn more about our technology as well as technologies in development, please visit [www.csamedical.com](http://www.csamedical.com).

###